GGrantIndex
← Leaderboards

Children'S Hospital & Res Ctr At Oakland

Oakland, CA

Compare ↔
$224,093,763
Total funding
132
Grants

Funding over time

peak $28.2M · FY2006–21
$50M$37.5M$25M$12.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$216,840,399 · 126
CDC$3,916,907 · 3
FDA$3,336,457 · 3

By mechanism

R01$105,404,517 · 54
U01$59,421,687 · 9
P50$13,518,477 · 6
U19$12,841,916 · 1
R21$7,335,438 · 20
U54$5,049,564 · 8

Investigators at Children'S Hospital & Res Ctr At Oakland

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Peter T. Beernink$8,574,1914 gr2Marisa Wong Medina$6,557,8595 gr3Edward James Lammer$4,753,1342 gr4Dario Boffelli$4,623,2565 gr5Nathalie Bergeron$4,314,9482 gr6Laura Hertel$3,468,4964 gr7June M Tester$2,387,9872 gr8Giorgio Cavigiolio$1,991,3851 gr

Largest grants

High-throughput targeted mutagenesis of mouse stem cell lines$5,100,000
U01 · FY2009 · HG
High-throughput targeted mutagenesis of mouse stem cell lines$4,811,326
U01 · FY2006 · HG
High-throughput targeted mutagenesis of mouse stem cell lines$4,689,520
U01 · FY2009 · HG
High-throughput targeted mutagenesis of mouse stem cell lines$4,687,520
U01 · FY2010 · HG
High-throughput targeted mutagenesis of mouse stem cell lines$4,687,500
U01 · FY2008 · HG
High-throughput targeted mutagenesis of mouse stem cell lines$4,114,426
U01 · FY2007 · HG
Northern California Comprehensive Sickle Cell Centers$3,557,214
U54 · FY2007 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$3,049,802
U01 · FY2006 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$2,935,651
U01 · FY2007 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$2,850,491
U01 · FY2008 · HL
Pharmacogenomics of Statin Therapy$2,836,708
P50 · FY2015 · GM
Pharmacogenomics of Statin Therapy$2,741,022
P50 · FY2016 · GM
Pharmacogenomics of Statin Therapy$2,688,571
P50 · FY2017 · GM
Pharmacogenomics of Statin Therapy$2,667,664
P50 · FY2018 · GM
Pharmacogenomics and Risk of Cardiovascular Disease$2,647,964
U19 · FY2010 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$2,595,709
U19 · FY2011 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$2,584,979
U19 · FY2012 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$2,555,469
U19 · FY2014 · HL
Pharmacogenomics and Risk of Cardiovascular Disease$2,457,795
U19 · FY2013 · HL
NORTHERN CALIFORNIA COMPREHENSIVE SICKLE CELL CENTERS$2,398,888
U54 · FY2006 · HL